Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ICMT | O60725 | 1/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1360017 | 0.97 | MAPT (0.36) | MAPTTSHRTHRBMAPK1POLB | |
| SCHEMBL1361418 | 0.93 | MAPT (0.42) | MAPTTHRBMAPK1POLBTP53 | |
| SCHEMBL1361746 | 0.93 | GCGR (0.38) | MAPTPOLBTP53L3MBTL1GCGR | |
| SCHEMBL1361106 | 0.92 | TUBB4A (0.35) | MAPTL3MBTL1ICMTGCGRNPC1 | |
| SCHEMBL1361656 | 0.92 | MAPT (0.39) | MAPTTSHRMAPK1POLBTP53 | |
| SCHEMBL1363090 | 0.92 | SMN1; SMN2 (0.36) | MAPTTSHRTHRBMAPK1ALDH1A1 | |
| SCHEMBL203742 | 0.91 | TP53 (0.41) | MAPTTSHRMAPK1POLBTP53 | |
| Hydrochloric Acid SCHEMBL1362475 | 0.91 | TP53 (0.41) | MAPTTSHRMAPK1POLBTP53 | |
| SCHEMBL1361745 | 0.90 | POLB (0.38) | MAPTPOLBTP53L3MBTL1GCGR | |
| SCHEMBL1361779 | 0.90 | GCGR (0.34) | MAPTPOLBTP53GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | claimed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | claimed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | claimed |
| US-6498179-B1 | SUCH AS 4-(4-CHLOROPHENYL)-5-(3-(2-METHOXYPHENOXY)PROPYL)-2-(2-METHYL-1 -IMIDAZOLYL)OXAZOLE; INSULIN SECERTION PROMOTING AND BLOOD SUGAR DEPRESSING EFFECT; DIABETES; LOW TOXICITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | claimed |
| US-20130310321-A1 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP | DAIICHI PURE CHEMICALS CO., LTD. (JP) | 2013-11-21 | — | — | US | disclosed |
| EP-1491194-B1 | VDAC REGULATOR | TAKEDA PHARMACEUTICAL (JP) | 2013-10-30 | — | — | EP | disclosed |
| EP-1407770-B1 | TGF-BETA SUPERFAMILY PRODUCTION/SECRETION PROMOTER | TAKEDA PHARMACEUTICAL (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-1548435-B1 | DIAGNOSTIC METHOD FOR EATING DISORDERS | IYO MASAOMI (JP) | 2012-05-23 | — | — | EP | disclosed |
| US-20120122777-A1 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP | Masao Daimon (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-7754434-B2 | Diagnostic and examination method for eating disorder | Iyo, Masaomi (JP) | 2010-07-13 | — | — | US | disclosed |
| EP-1407770-A1 | TGF-BETA SUPERFAMILY PRODUCTION/SECRETION PROMOTER | Takeda Chemical Industries, Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| US-6498179-B1 | SUCH AS 4-(4-CHLOROPHENYL)-5-(3-(2-METHOXYPHENOXY)PROPYL)-2-(2-METHYL-1 -IMIDAZOLYL)OXAZOLE; INSULIN SECERTION PROMOTING AND BLOOD SUGAR DEPRESSING EFFECT; DIABETES; LOW TOXICITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-24 | — | — | US | disclosed |
| EP-0891340-B1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | disclosed |
| US-6177452-B1 | ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-23 | — | — | US | disclosed |
| EP-0891340-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036882-A1 | OXAZOLE DERIVATIVES, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | MAPT 3908/4885TSHR 196/4885THRB 164/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | MAPT 4720/4885TSHR 237/4885THRB 180/4885 |
| US-20120122777-A1 | DIAGNOSTIC AGENT FOR ISCHEMIC HEART DISEASE RISK GROUP | BDNF, NGF, FABP3 | MAPT 3059/4885TSHR 1316/4885THRB 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.